Navigation Links
Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
Date:4/7/2008

LA JOLLA, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) announced today that based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission the Company can initiate its Phase 3 clinical program for its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID"), Ketotransdel(TM). Transdel Pharmaceuticals is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically administered medications.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "I am pleased to announce that the FDA has reviewed our February 7, 2008 FDA submission and has stated that it is safe to proceed with the Phase 3 program. The FDA also noted that there are no clinical hold issues and provided comments regarding the registration requirements of our lead drug. We will continue our discussions with the FDA regarding the final product approval requirements." Dr. Singh continued, "Advancing into Phase 3 clinical studies for Ketotransdel marks a significant milestone for the Company. Our dedicated and committed team is focused on successfully advancing our topical drug to FDA approval."

Based on industry estimates, the market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year; more than 30 million people worldwide use NSAIDs daily. Due to the recognition of known risks associated with orally administered NSAIDs, including cardiovascular, gastrointestinal and other medical complications, and the decline in the use of Cox-2 inhibitors because of safety concerns, Transdel believes that there is a significant demand for topical pain management products such as Ketotransdel. Moreover, the Company expects that Ketotransdel, if approved by the FDA, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address a significant unmet medical need for patients with medical conditions and those patients seeking safer alternatives to the standard pain management approaches.

In the second quarter of 2008, the Company intends to initiate the randomized, double-blind, placebo controlled Phase 3 program to evaluate the efficacy and safety of Ketotransdel in acute pain care management. The Company also stated that in the near term it will be announcing organizational changes as the company transitions into late stage clinical phase.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel, utilizes the Company's innovative patented Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug can exert its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at http://www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the company assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical ... ("Precision Lens"), today announced the signing of a ... Precision Lens will deploy a dedicated sales team ... in the U.S., primarily focused in 13 states ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 2017 , ... Life of Purpose Treatment is proud to present “An Evening ... at 7:30 pm on May 10th at the University Auditorium. , This benefit concert, ... support the UF Collegiate Recovery Community (UFCRC). The concert will kick off the 5th ...
(Date:4/23/2017)... ... April 23, 2017 , ... ... services announced the achievement of Cisco Select certification and SMB specialization. Altura ... States. , In earning the Select Certification, Altura fulfilled the training ...
(Date:4/22/2017)... ... , ... The San Juan Capistrano summer camp team at the Boys and Girls ... summer camps to provide physical activities for all campers. To read the report, click ... With an increase in specialty camps that focus on what the report terms as “sitting ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Chicago plastic ... the removal of osteoma. An osteoma is a benign bony lump located on the ... eye and can cause difficulties with sight and pain. Dr. Shah has discovered an ...
(Date:4/21/2017)... ... ... The adage “Show, don’t tell” applies perfectly to Green Builder Media’s Earth ... House demonstration project series. Manifesting the concept of right-sized living, the Flex House is ... affordably and abundantly without unduly taxing the resources of our beautiful planet. ...
Breaking Medicine News(10 mins):